BIT Capital’s Jasper Therapeutics JSPR Stock Holding History

BIT Capital’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-100	Closed	-$57.9K	–	158
2022 Q2	$57.9K	Hold	100	–	–	0.01%	104
2022 Q1	$106K	Buy	+100	New	+$135K	0.01%	103

Other funds holding JSPR

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Abingworth London, United Kingdom $304M AUM 95.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

Fernwood Investment Management Quincy, Massachusetts $288M AUM 33.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

BIT Capital's JSPR Position: Q3 2022 in Review

BIT Capital sold out of Jasper Therapeutics (JSPR) in Q3 2022, closing a stake of 100 shares — an estimated $57.9K sold.

BIT Capital first reported a position in JSPR in Q1 2022 and held it in 2 quarters. The position peaked at $106K in Q1 2022. 22 funds tracked by Wall St. Rank hold JSPR as of Q3 2022.

BIT Capital reported no remaining Jasper Therapeutics position as of Q3 2022 after selling out during the quarter.
BIT Capital sold 100 Jasper Therapeutics shares in Q3 2022, an estimated $57.9K.
BIT Capital first reported a position in Jasper Therapeutics in Q1 2022 and held it in 2 quarters.
BIT Capital's Jasper Therapeutics position peaked at $106K in Q1 2022.
22 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2022.

Based on BIT Capital's 13F filing for Q3 2022, filed 12 Feb 2025.